Latest Breaking News On - பூல்ட் கண்காணிப்பு - Page 1 : comparemela.com

(2) - Early and Cost-Effective Identification of Samples Potentially Containing the B.1.1.7 or Other Variants May Help Reduce Further Spread of Infection - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company ), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) published a safety communication (the Communication ) that identifies the Company s Linea COVID-19 Assay Kit (the Assay Kit ) as one of only two tests marketed under the FDA s Emergency Use Authorization (EUA) that are potentially able to identify certain SARS-CoV-2 mutations, including a mutation found in the U.K. variant of SARS-CoV-2 (B.1.1.7). According to recent publications, the B.1.1.7 variant has been identified within the United States and may be associated with an increased risk of transmission of the virus that causes COVID-19. The identification of certain mutations can help identify samples that should be further characteriz

United statesJamesa haywardMike munzerSciences incDrug administrationCompany assay kitClinical laboratory improvement amendmentsCompany lineaSecurities exchangeYork state department of healthCost effective identificationSamples potentially containingPolymerase chain reactionUse authorizationAssay kitPooled surveillance